OUR LEADERSHIP
… is focused on developing breakthrough treatments that will repair, rewire and heal the brain.
OUR MANAGEMENT TEAM
Douglas Drysdale
Executive Chairman
- Globally recognized thought leader and transformative strategist with over 35 years in healthcare and pharmaceuticals
- Formerly CEO Cybin Inc; CEO Tedor Pharma Inc; Chairman & CEO Pernix Therapeutics; and Founder & CEO Alvogen Inc.
- See Bio
Ahmad Doroudian, PhD
Chief Executive Officer & Director
- 20+ years experience as a Pharma CEO in finance, including M&A, and multiple IPOs, integration of pharmaceutical operations (Whitehall Robbins, Rhone Polenc, Boehringer, Aventis)
- Founder of Merus Labs (NASDAQ: MSLI), sold for $300 M+ in 2017
- Acquisition, integration, tech transfer and management of branded pharmaceutical products Enablex®/Emselex®, Entrophen®, Sandomigran®, Sintrom®, Vancocin®, Zaditen®
Hooshmand Sheshbaradaran, PhD
Chief Operating Officer
- 30+ years senior pharma executive with experience in global drug development, marketing, business strategy, operations, licensing and M&A
- Senior executive roles at Pharmacia/Pfizer, Roche, Zeneus/Cephalon, Niiki Pharma, Psioxus
- Development of Camptosar®, Ellence®, Emcyt®, Sutent® and Vidaza®.
Moira Ong, CPA, CA
Chief Financial Officer
- 20+ years experience in financial reporting, compliance and audit.
- Managed the integration of the supply chain management and accounting for Vancocin, Enablex®/Emselex®, acquired from Novartis, by Merus Labs International Inc. (formerly NASDAQ: MSLI)
- Previously at Grant Thornton, Deloitte & Touche
Scott Rudge, PhD
Head CMC
- Founded CMC development expert services group in 2004, has worked on over 200 projects for all molecule/therapy classes since
- Site Director & VP Operations for FeRx; increasing management responsibility at NIST, Synergen, Amylin
- PhD in Chemical Engineering from Purdue and author of multiple peer reviewed articles, book chapters and an award-winning textbook
Abdi Ghaffari, PhD
- 15+ years pharma executives with experience in nonclinical pharmacology and toxicology in fields of neuropsychiatric disorders, oncology, and respiratory infection.
- Senior scientist roles at PulmoNOx, Beyond Air, Novateur, and Tika Therapeutics.
OUR ADVISORS / COLLABORATORS
OUR BOARD OF DIRECTORS
Ahmad Doroudian, PhD
- 20+ years experience as a Pharma CEO in finance, including M&A, and multiple IPOs, Integration of pharmaceutical operations (Whitehall Robbins, Rhone Polenc, Boehringer, Aventis)
- Founder of Merus Labs (NASDAQ: MSLI), sold for $300 M+ in 2017
- Acquisition, integration, tech transfer and management of branded pharmaceutical products Enablex®/Emselex®, Entrophen®, Sandomigran®, Sintrom®, Vancocin®, Zaditen®
Douglas Drysdale
Executive Chairman
- Globally recognized thought leader and transformative strategist with over 35 years in healthcare and pharmaceuticals
- Formerly CEO Cybin Inc; CEO Tedor Pharma Inc; Chairman & CEO Pernix Therapeutics; and Founder & CEO Alvogen Inc.
- See Bio
John W. LaRocca, Esq.
- Over 26 years of executive legal leadership in the biotechnology and pharmaceutical industries, with expertise spanning clinical development, commercialization, and strategic transactions.
- Proven track record executing transformative transactions, including the approximately US$930 million sale of Aerie Pharmaceuticals, overseeing more than US$100 billion in acquisitions, and negotiating significant international licensing agreements.
- Accomplished legal strategist with experience building legal and compliance organizations, managing complex litigation, and securing a landmark U.S. Supreme Court victory that reshaped product liability law for the generic pharmaceutical industry.
Ralph Anthony Pullen
- Investment banker in the healthcare and biotechnology industry sectors
- Instrumental in the creation and funding of MDS Capital Corp., Canada’s largest venture capital fund dedicated to the life sciences, now known as Lumira Capital where he served as a board member
Dr. Steven Sangha
- 25+ years of experience in investment banking, business development and asset management.
- Extensive experience with public company governance, compliance and finance has led Dr. Sangha to run a successful private fund family office.
- Interest in the biotechnology and mining industries has allowed positive growth for early-stage companies with Dr. Sangha’s consummate efforts in assessment, development and financial support.
- Doctorate of Dental Surgery (University of Western Ontario, London, Ontario) and a Bachelor of Pharmaceutical Science (University of British Columbia, Vancouver, British Columbia).
